{
    "nct_id": "NCT03935282",
    "official_title": "Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (AH-HA)",
    "inclusion_criteria": "* >= 6 months post-potentially curative cancer treatment for breast, prostate, colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas. Ongoing hormonal therapies such as tamoxifen, aromatase inhibitors (with or without adjuvant CDK 4/6 inhibitors such as abemaciclib), or androgen deprivation are allowed.\n* Scheduled for a routine cancer-related follow-up care visit within the next 30 days with a provider who received training to use AH-HA.\n* Able and willing to complete a follow-up assessment in one year.\n* Survivors must have no evidence of disease at the time of last medical visit for all cancers, except non-melanoma skin disease.\n* Age >= 18 years.\n* Able to understand and willing to provide verbal informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Survivors will be excluded if they have a history of cancer recurrence for any cancer other than non-melanoma skin disease.\n* Prostate patients on active surveillance will be excluded.\n* Survivor does not speak English or Spanish.\n* Survivors who are currently on another interventional protocol in which cardiovascular risk factors (e.g., blood pressure, smoking, diet, physical activity) are being addressed, as per patient self-report or research staff members' knowledge at the time of consent.",
    "miscellaneous_criteria": ""
}